Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection

Vaccine

Volumn 32, Issue 43, 2014, Pages 5761-5768

  Sharma, Anurag ^a   Wendland, Rebecca ^a   Sung, Biin ^a   Wu, Wenzhu ^a   Grunwald, Thomas ^b,c   Worgall, Stefan ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

Author keywords

Chimpanzee adenoviral vector; Maternal immunization; Respiratory syncytial virus; RSV vaccine

Indexed keywords

ADENOVIRUS VECTOR; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS ANTIBODY;

ADENOVIRUS 7; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CODON; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; HUMORAL IMMUNITY; INFANT; MOUSE; MUCOSAL IMMUNITY; NEWBORN; NEWBORN INFECTION; NONHUMAN; PASSIVE IMMUNIZATION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVACCINATION; VACCINATION; VIRUS REPLICATION; ADENOVIRIDAE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CROSS REACTION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; FEMALE; IMMUNITY, HUMORAL; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNITY, MUCOSAL; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL FUSION PROTEINS;

EID: 84908416331     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.049     Document Type: Article

References (50)

1. Shay D.K., Holman R.C., Roosevelt G.E., Clarke M.J., Anderson L.J. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001, 183(1):16-22.
2. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375(9725):1545-1555.
3. Collins P.L., Melero J.A. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011, 162(1/2):80-99.
4. Sommer C., Resch B., Simoes E.A. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J 2011, 5:144-154.
5. Kalina W.V., Gershwin L.J. Progress in defining the role of RSV in allergy and asthma: from clinical observations to animal models. Clin Dev Immunol 2004, 11(2):113-119.
6. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998, 102(3 Pt 1):531-537.
7. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89(4):422-434.
8. Habibi M.S., Openshaw P.J. Benefit and harm from immunity to respiratory syncytial virus: implications for treatment. Curr Opin Infect Dis 2012, 25(6):687-694.
9. Krause A., Xu Y., Ross S., Wu W., Joh J., Worgall S. Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine. Virol J 2011, 8:375.
10. Johnson T.R., Rangel D., Graham B.S., Brough D.E., Gall J.G. Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Mol Ther 2014, 22(1):196-205.
11. Kohlmann R., Schwannecke S., Tippler B., Ternette N., Temchura V.V., Tenbusch M., et al. Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J Virol 2009, 83(23):12601-12610.
12. Grunwald T., Tenbusch M., Schulte R., Raue K., Wolf H., Hannaman D., et al. Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates. J Virol 2014, 88(8):3997-4007.
13. Kim E., Okada K., Beeler J.A., Crim R.L., Piedra P.A., Gilbert B.E., et al. Development of an adenoviral-based RSV vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model. J Virol 2014, 88(9):5100-5108.
14. Santosuosso M., McCormick S., Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 2005, 18(2):283-291.
15. Tatsis N., Ertl H.C. Adenoviruses as vaccine vectors. Mol Ther 2004, 10(4):616-629.
16. Ahi Y.S., Bangari D.S., Mittal S.K. Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther 2011, 11(4):307-320.
17. Krause A., Whu W.Z., Qiu J., Wafadari D., Hackett N.R., Sharma A., et al. RGD capsid modification enhances mucosal protective immunity of a non-human primate adenovirus vector expressing Pseudomonas aeruginosa OprF. Clin Exp Immunol 2013, 173(2):230-241.
18. Krause A., Whu W.Z., Xu Y., Joh J., Crystal R.G., Worgall S. Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF. Vaccine 2011, 29(11):2131-2139.
19. Hall C.B., Walsh E.E., Long C.E., Schnabel K.C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991, 163(4):693-698.
20. Piedra P.A., Jewell A.M., Cron S.G., Atmar R.L., Glezen W.P. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003, 21(24):3479-3482.
21. Ogilvie M.M., Vathenen A.S., Radford M., Codd J., Key S. Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol 1981, 7(4):263-271.
22. Piedra P.A. Clinical experience with respiratory syncytial virus vaccines. Pediatr Infect Dis J 2003, 22(2 Suppl.):S94-S99.
23. Stensballe L.G., Ravn H., Kristensen K., Meakins T., Aaby P., Simoes E.A. Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus. J Pediatr 2009, 154(2):296-298.
24. Kaaijk P., Luytjes W., Rots N.Y. Vaccination against RSV: is maternal vaccination a good alternative to other approaches?. Hum Vaccin Immunother 2013, 9(6):1263-1267.
25. Reyes-Sandoval A., Fitzgerald J.C., Grant R., Roy S., Xiang Z.Q., Li Y., et al. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol 2004, 78(14):7392-7399.
26. Hashimoto M., Boyer J.L., Hackett N.R., Wilson J.M., Crystal R.G. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect Immun 2005, 73(10):6885-6891.
27. Mittereder N., March K.L., Trapnell B.C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996, 70(11):7498-7509.
28. Sharma A., Tandon M., Ahi Y.S., Bangari D.S., Vemulapalli R., Mittal S.K. Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. Gene Ther 2010, 17(5):634-642.
29. Ferreira T.B., Alves P.M., Aunins J.G., Carrondo M.J. Use of adenoviral vectors as veterinary vaccines. Gene Ther 2005, 12(Suppl. 1):S73-S83.
30. Chirmule N., Propert K., Magosin S., Qian Y., Qian R., Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999, 6(9):1574-1583.
31. Hackett N.R., Kaminsky S.M., Sondhi D., Crystal R.G. Antivector and antitransgene host responses in gene therapy. Curr Opin Mol Ther 2000, 2(4):376-382.
32. Bangari D.S., Mittal S.K. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 2006, 24(7):849-862.
33. Colloca S., Barnes E., Folgori A., Ammendola V., Capone S., Cirillo A., et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012, 4(115):115ra2.
34. Sharma A., Bangari D.S., Tandon M., Pandey A., HogenEsch H., Mittal S.K. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 2009, 386(1):44-54.
35. Tatsis N., Tesema L., Robinson E.R., Giles-Davis W., McCoy K., Gao G.P., et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 2006, 13(5):421-429.
36. Fu Y.H., He J.S., Qiao W., Jiao Y.Y., Hua Y., Zhang Y., et al. Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice. Virol J 2013, 10:183.
37. Stockman L.J., Curns A.T., Anderson L.J., Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 2012, 31(1):5-9.
38. Philbin V.J., Levy O. Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. Pediatr Res 2009, 65(5 Pt 2):98R-105R.
39. Crowe J.E., Firestone C.Y., Murphy B.R. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol 2001, 167(7):3910-3918.
40. Gimenez H.B., Chisholm S., Dornan J., Cash P. Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies. Clin Diagn Lab Immunol 1996, 3(3):280-286.
41. Graham B.S. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2010, 239(1):149-166.
42. Kwon Y.M., Hwang H.S., Lee J.S., Ko E.J., Yoo S.E., Kim M.C., et al. Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease. Antiviral Res 2014, 104:1-6.
43. Shaw C.A., Ciarlet M., Cooper B.W., Dionigi L., Keith P., O'Brien K.B., et al. The path to an RSV vaccine. Curr Opin Virol 2013, 3(3):332-342.
44. Healy C.M. Vaccines in pregnant women and research initiatives. Clin Obstet Gynecol 2012, 55(2):474-486.
45. Munoz F.M., Piedra P.A., Glezen W.P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003, 21(24):3465-3467.
46. O'Hara G.A., Duncan C.J., Ewer K.J., Collins K.A., Elias S.C., Halstead F.D., et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012, 205(5):772-781.
47. Ledgerwood J.E., Costner P., Desai N., Holman L., Enama M.E., Yamshchikov G., et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010, 29(2):304-313.
48. Capone S., D'Alise A.M., Ammendola V., Colloca S., Cortese R., Nicosia A., et al. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines 2013, 12(4):379-393.
49. Moro P.L., Broder K., Zheteyeva Y., Walton K., Rohan P., Sutherland A., et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. Am J Obstet Gynecol 2011, 204(2):146.e1-146.e7.
50. McLellan J.S., Chen M., Joyce M.G., Sastry M., Stewart-Jones G.B., Yang Y., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013, 342(6158):592-598.